NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founde ...

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Pet DNA Testing Market Size, Share and Trends Analysis 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global pet DNA testing market is expected to reach USD 676.64 million by 2030, registering to grow at a CAGR of 9.45% from 2024 to 2030. The key factors driving the industry growth include a rise in consumer genomics, high pet expenditure & pet humanization, increased awareness & sale of pet DNA testing products, and an increase in t ...

The latest trading session saw Ginkgo Bioworks Holdings, Inc. (DNA) ending at $7.70, denoting a -0.77% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%. The company's stock has climbed by 9.6% in the past month, exceeding the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the performance of Ginkgo Bioworks Holdings, Inc. in its f ...

Venlo, The Netherlands, and Hombrechtikon, Switzerland, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PreAnalytiX GmbH, a joint venture between QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) and BD (Becton, Dickinson and Company; NYSE: BDX), today announced the launch of the PAXgene® Urine Liquid Biopsy Set, which enables the reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). The new set will be com ...

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremel ...

BOSTON and CHESTERFIELD, Mo., Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced costeff ...

OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. ("Ginkgo," includ ...

BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoi ...

The company is forging ahead with next-generation drug development solutions. Bioengineering specialist Ginkgo Bioworks Holdings (DNA 9.31%) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index. Two new products introduced Ginkgo's news was c ...

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON, Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that ...